Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for advanced renal cell carcinoma (RCC), but only a subset of patients achieve durable clinical benefit. Because T-cell receptor (TCR)-mediated antigen recognition is central to antitumor immunity, characterization of the intratumoral TCR repertoire could yield tissue biomarkers to stratify patients before treatment. This study examined whether baseline intratumoral TCRβ and TCRγ repertoire features predict clinical response to ICIs in a real-world cohort of patients with advanced RCC predominantly treated with first-line ICI-based regimens.
The analysis used an exploratory, real-world cohort of patients with advanced RCC who received ICI-based therapy, mostly in the first-line setting. The study is reported as a medRxiv preprint and has not been peer reviewed. Ethical approvals were obtained from the Clinical Research Ethics Committee of Galicia (CEIm-G; 2022/429) and the Clinical Research Ethics Committee of Hospital 12 de Octubre (18/055). The authors note that datasets supporting the findings are available from corresponding authors on reasonable request.
Baseline intratumoral samples were profiled for both TCRβ and TCRγ repertoires. The study compared repertoire metrics between patients who subsequently responded to ICI therapy and those who did not. Reported repertoire attributes included evenness, diversity, clonal richness, and clonal dominance, and the analysis included assessment of TRBV gene usage.
Responders demonstrated a significantly more even TCRβ repertoire at baseline compared with non-responders. Increased evenness of the TCRβ repertoire in responders suggests a broader distribution of productive T-cell clonotypes rather than dominance by a few clones.
Baseline TCRγ repertoire differences were also associated with outcome. Responders exhibited increased TCRγ diversity and greater clonal richness, while non-responders showed higher TCRγ clonal dominance. These contrasting patterns indicate that TCRγ repertoire architecture may capture distinct aspects of intratumoral immune competence relevant to ICI sensitivity.
The study observed preferential usage of several TRBV genes associated with clinical response and longer progression-free survival. Reported TRBV gene segments linked to response included TRBV5.7, TRBV7.1, and TRBV18. The authors present this preferential TRBV usage as an additional repertoire-level correlate of benefit from checkpoint blockade in advanced RCC.
To assess combined predictive value, the most informative TCRβ and TCRγ variables were integrated into a random forest classifier. In leave-one-out cross-validation, the combined model yielded an area under the receiver operating characteristic curve (AUC) of 0.90. At the selected operating threshold, model performance was reported as 100% sensitivity and 81.8% specificity. These metrics are presented for this exploratory cohort and support the concept that integrated TCR repertoire features can discriminate responders from non-responders.
The authors interpret the results as evidence that baseline intratumoral TCR repertoire characteristics—encompassing both TCRβ evenness and TCRγ diversity/richness, plus specific TRBV gene usage—are candidate tissue biomarkers for pretreatment stratification of advanced RCC patients considered for ICI therapy. The study is presented as the first to simultaneously profile baseline intratumoral TCRβ and TCRγ repertoires in this clinical context, and the authors argue the findings provide rationale for prospective validation of TCR repertoire profiling as a predictor of immunotherapy benefit in RCC.
This report is a medRxiv preprint and has not been certified by peer review; the authors explicitly note it should not guide clinical practice. The cohort is described as exploratory and real-world; details such as cohort size, full demographic or treatment breakdowns, and complete analytic methods are provided in the manuscript but are not enumerated in the abstract. Prospective validation and independent replication are needed before clinical implementation.
Ethical approvals were obtained from CEIm-G (2022/429) and Hospital 12 de Octubre (18/055). The authors declare no competing interests. Datasets supporting the findings are available from corresponding authors upon reasonable request. Declared funders include Instituto de Salud Carlos III (PI21/00348, CP20/00188), Ministerio de Ciencia, Innovación y Universidades (FPU23/00744), and Axencia Galega de Innovacion (IN606B-2024/014). The preprint was posted September 06, 2026.
In this exploratory dataset of advanced RCC patients predominantly treated with first-line ICI regimens, baseline intratumoral TCRβ and TCRγ repertoire features—together with preferential TRBV usage—were associated with response and progression-free survival. A combined random forest model integrating these features achieved high discriminatory performance in cross-validation (AUC 0.90). The authors propose that baseline intratumoral TCR repertoire profiling merits prospective validation as a predictive tissue biomarker for ICI benefit in RCC.